Make informed decisions about clinical trial adverse drug events
MedWise® Polypharmacy Biosimulation enables pharmaceutical manufacturers and regulatory agencies to optimize early and late-stage clinical development, regulatory, and commercial decisions in real-world populations: New Molecular Entities’ (NME), Investigational New Drug (IND) and New Drug Applications (NDA), Safety-related Label Changes (SrLC), Risk Evaluation & Mitigation Strategies (REMS), Periodic Safety Update Reports (PSUR), and Post-market Spontaneous Adverse Event Reports (AER).
Leverage MedWise® Science to optimize clinical development
MedWise® Science —a proprietary system that identifies potential multi-drug interactions in aggregate—powers our Polypharmacy Biosimulation offering. This unique tool allows simultaneous evaluation of multiple prescription medications, and supplements to predict complex multi-drug interactions that traditional methods miss.
Patients enrolled in studies of new drugs intended for chronic use often have comorbidities and may be on several medications. Identifying potential drug interactions before they arise will lead to better outcomes and more informed regulatory and commercial decisions.
MedWise Science can also simulate patient demographics including race, ethnicity and age. This powerful tool can even create a simulation to predict outcomes for patients with comorbidities that would preclude them from trial enrollment.
MedWise Polypharmacy Simulation helps clinical development professionals create or refine:
See how MedWise Polypharmacy Biosimulation can help your team
Complete the form below to review a free comprehensive impact assessment! A TRHC Life Sciences representative will be in touch shortly.